Since RGD fiber-mutant adenovirus vector (AdRGD), which contains an av-integrin tropism, is highly efficient in gene transduction to melanoma, the AdRGD-mediated herpes simplex virus thymidine kinase (HSVtk)/ganciclovir (GCV) system is an attractive approach for melanoma treatment. However, the intratumoral injection of AdRGD causes limited transgene expression in healthy normal tissue, due to unwanted vector spread. Herein, we describe our attempt to overcome this limitation related to the safety of HSVtk/GCV treatment by using AdRGD carrying either melanoma-specific tyrosinase (Tyr) promoter or tumor-specific telomerase reverse transcriptase (TERT) promoter instead of universal cytomegalovirus promoter. Our in vitro study revealed that Tyr promoterregulated AdRGD exhibited high transgene expression specificity for melanoma cells, and that TERT promoter-regulated AdRGD could induce efficient gene expression in tumor cells, but was relatively quiescent in normal cells. Anti-B16BL6 melanoma effects in mice injected intratumorally with AdRGD-Tyr/HSVtk or AdRGD-TERT/HSVtk, after which GCV was injected intraperitoneally for 10 days, were comparable to those in mice injected with AdRGD-CMV/HSVtk at 10 times less vector dosage. On the other hand, AdRGD-Tyr/HSVtk and AdRGD-TERT/HSVtk did not induce severe adverse effects even when they were intravenously injected into mice at 10 9 plaque-forming units (PFU), whereas mice injected with AdRGD-CMV/HSVtk at 10 8 PFU exhibited body weight reduction and serum level increase of biochemical enzymes for hepatotoxicity. These results indicate that AdRGD combined with transcriptional regulation using Tyr or TERT promoter is a potentially useful and safe vector system for suicide gene therapy for melanoma.
C urrently, various strategies of gene therapy have been proposed for improving the cure rate of patients with melanoma, 1 whose prognosis is generally poor even after conventional treatment, such as surgery, chemotherapy, and radiotherapy. 2, 3 Suicide gene therapy is a promising approach for melanoma, and the HSVtk/GCV system, which includes transduction of the herpes simplex virus thymidine kinase (HSVtk) gene followed by administration of the antiviral prodrug ganciclovir (GCV), has been the most widely studied method in preclinical and clinical settings. [4] [5] [6] [7] [8] [9] [10] Since HSVtk is an enzyme that converts nontoxic GCV to a highly toxic GCV-triphosphate, HSVtk-transduced cells render themselves sensitive to GCV, resulting in cell death. Moreover, an important advantage of the HSVtk/GCV system is the bystander effect, which confers cytotoxicity to untransduced cells adjacent to HSVtk-expressing cells by the transfer of GCV-triphosphate through gap junctions. [11] [12] [13] We previously demonstrated that RGD fiber-mutant adenovirus vector (AdRGD), which contains an avintegrin tropism due to an RGD peptide inserted into the HI loop of the fiber knob, was superior to conventional adenovirus vector (Ad) in gene transduction efficiency to melanoma both in vitro and in vivo. [14] [15] [16] In addition, Mizuguchi et al 17 reported that the intratumoral injection of AdRGD expressing the HSVtk gene under the control of the cytomegalovirus (CMV) promoter, followed by intraperitoneal GCV administration, was approximately 25 times more effective at inducing tumor regression in established murine B16BL6 melanoma than injection of conventional Ad carrying the same expression cassette. These results suggest that AdRGD is a useful vector system for developing efficacious suicide gene therapy for melanoma because of its predominancy in gene transduction efficacy. However, we also found that AdRGD leaked from the injected tumor site into systemic circulation even if we carefully injected small volumes of AdRGD, and that a large fraction of the leaked AdRGD accumulated in the liver. 18 A major drawback of universal CMV promoterbased suicide gene therapy for cancer is the lack of selectivity for tumor cells in transgene expression accompanied by high probability for toxicity in normal healthy tissue. [19] [20] [21] Therefore, the ability to restrict gene expression to tumor cells is essential for assuring the safety of suicide gene therapy.
One possible approach to site-restricted suicide gene expression is the use of tissue-specific regulatory elements. For example, the tyrosinase (Tyr) promoter appears suitable for specific gene expression in melanoma cells. Tyr is a key enzyme in melanogenesis and is specifically expressed in pigmented cells including melanoma cells. 22, 23 Likewise, telomerase reverse transcriptase (TERT) promoter would be a useful candidate for targeting transgene expression in cancer cells, [24] [25] [26] [27] because TERT, the catalytic subunit of telomerase, is highly active in tumor cells but inactive in most normal cells. [28] [29] [30] Thus, in the present study, we constructed two new AdRGDs that express HSVtk gene under control of the Tyr or TERT promoter, and compared efficacy and toxicity of suicide gene therapy using these tumor-specific AdRGDTyr/HSVtk and AdRGD-TERT/HSVtk with those using AdRGD-CMV/HSVtk.
Materials and methods

Cell lines and mice
Murine melanoma B16BL6 cells and human normal fibroblast WI-38 cells were cultured in minimum essential medium supplemented with 10% fetal bovine serum (FBS) and antibiotics. Human melanoma A2058 cells, human alveolar adenocarcinoma A549 cells, and 293 cells, the helper cell line for AdRGD-expansion, were grown in Dulbecco's modified Eagle's medium supplemented with 10% FBS and antibiotics. Murine colon carcinoma Colon-26 cells were grown in RPMI 1640 medium supplemented with 10% FBS and antibiotics. Female C57BL/6 mice, aged 6-7 weeks, were purchased from SLC Inc. (Hamamatsu, Japan) and were held under specified pathogen-free conditions. Animal experimental procedures were in accordance with the Osaka University guidelines for the welfare of animals in experimental neoplasia.
Cloning of the human TERT promoter
The human TERT promoter immediately upstream of the transcription start site (positions À378 to þ 77) 29 was amplified from human genomic DNA by polymerase chain reaction. The sequences of the specific primers were as follows: forward (5 0 -TGGCCCCTCCCTCGGGTT AC-3 0 ) and reverse (5 0 -CGCGGGGGTGGCCGGGG C-3 0 ). The amplified 455 bp fragment was subcloned into pGEM-3Zf(-) (Promega, Madison, WI), resulting in pGEM-hTERT2. The sequence was verified on a DNA sequencer (ABI PRISM 310, Applied Biosystems, Foster City, CA).
Vectors
Replication-deficient AdRGDs based on the adenovirus serotype 5 backbone with deletions of E1 and E3 regions were constructed by an improved in vitro ligation method using pAdHM15-RGD vector plasmid. [31] [32] [33] The AdRGD constructs are shown schematically in Figure 1 . AdRGD-CMV/Luc 15 and AdRGD-CMV/HSVtk, 17 which express luciferase and HSVtk, respectively, under the control of the CMV promoter, were previously constructed by using pCMVL1 33 and pHM3-CMVtk 17 as shuttle plasmids. The human Tyr promoter with dual tandem melanocytespecific (MS) enhancer was removed from pTyrex-2 34 (kindly provided by Dr DL Bartlett; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD) by restriction digest and inserted into pCMVL1 or pHM3-CMVtk instead of the human CMV immediate-early promoter and enhancer, resulting Figure 1 Schematic of AdRGDs used in this study. ITR, inverted terminal repeat; CMV prom, cytomegalovirus promoter; Tyr prom, tyrosinase promoter; MS enh, melanocyte-specific enhancer; TERT prom, telomerase reverse transcriptase promoter; Luc, firefly luciferase; HSVtk, herpes simplex virus thymidine kinase; P(A), polyadenylation signal.
Transcriptional targeting for suicide gene therapy Y Okada et al in pTyrL1 or pHM3-Tyrtk, respectively. Likewise, pTERTL1 or pHM3-TERTtk was constructed by replacement of CMV promoter in pCMVL1 or pHM3-CMVtk with the TERT promoter removed from pGEM-hTERT2 by restriction digest. Then, the I-Ceu I/PI-SceI-digested fragment from each shuttle plasmid (pTyrL1, pTERTL1, pHM3-Tyrtk, or pHM3-TERTtk) was ligated to I-CeuI/ PI-SceI-digested pAdHM15-RGD to create luciferaseexpressing vector plasmids (pAdHM15-RGD-Tyr/Luc and pAdHM15-RGD-TERT/Luc) and HSVtk-expressing vector plasmids (pAdHM15-RGD-Tyr/HSVtk and pAdHM15-RGD-TERT/HSVtk), respectively. To generate the viral vector particle (AdRGD-Tyr/Luc, AdRGD-TERT/Luc, AdRGD-Tyr/HSVtk, and AdRGD-TERT/ HSVtk), each vector plasmid was digested with PacI to release the recombinant viral genome and transfected into 293 cells plated on a 100-mm dish with SuperFect transfection reagent (Qiagen, Valencia, CA) according to the manufacturer's instructions. All recombinant AdRGDs were propagated in 293 cells, purified by two rounds of cesium chloride gradient ultracentrifugation, dialyzed, and stored at À801C. Titers (plaque-forming units, PFU) of infective AdRGD particles were evaluated by the end point dilution method using 293 cells.
In vitro gene expression analysis B16BL6, A2058, Colon-26, A549, and WI-38 cells were seeded onto 24-well plates at 5 Â 10 4 cells/well. On the following day, the cells were infected with AdRGD-CMV/Luc, AdRGD-Tyr/Luc, or AdRGD-TERT/Luc for 2 hours at 1 or 10 MOI (multiplicity of infection; PFU/ cell) in 100 ml of FBS-free medium. Culture medium was added to each well after washing twice with phosphatebuffered saline (PBS). After 2 days, luciferase activity in the cells was determined by a luciferase assay system (Promega).
In vitro cytotoxic assay B16BL6, Colon-26, and WI-38 cells were seeded onto 96-well plates at 4 Â 10 3 cells/well. The next day, the cells were infected with AdRGD-CMV/HSVtk, AdRGD-Tyr/ HSVtk, or AdRGD-TERT/HSVtk in 50 ml of FBS-free medium for 2 hours at MOI that did not induce cytopathic effects against the culture cells by transduction alone. The cells were then cultured in media containing GCV (Tanabe Pharmaceuticals, Osaka, Japan) at 0.08, 0.4, 2, or 10 mg/ml. After 4 days, cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Dojindo Laboratories, Kumamoto, Japan) assay according to the method described by Mosmann. 9 PFU, the tumor, liver, spleen, kidney, heart, lung, and brain were removed, weighed, and homogenized in PBS containing 10 mg/ml aprotinin and 100 mM phenylmethylsulfonyl fluoride. Luciferase activity in the homogenates was determined by the luciferase assay system. Likewise, intact mice were intravenously injected with each vector at 10 7 , 10 8 , or 10 9 PFU, and then luciferase activity of the liver, spleen, kidney, heart, lung, and brain was measured 2 days later.
Systemic toxicity of three types of HSVtk-expressing AdRGDs C57BL/6 mice were intravenously injected with AdRGD-CMV/HSVtk, AdRGD-Tyr/HSVtk, or AdRGD-TERT/ HSVtk at 10 8 or 10 9 PFU. The mice received daily injections of GCV (75 mg/kg) intraperitoneally for 6 days beginning the day after intravenous AdRGD-injection. Body weight was measured every day, and the relative body weight was calculated by the following formula: (relative body weight) ¼ (body weight after AdRGD treatment)/(body weight before AdRGD treatment). At 1 week after AdRGD injection, blood was collected from the tail vein of the mice, and the serum levels of glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) were measured using transaminase CII-testwako (Wako Pure Chemical Industries, Ltd., Osaka, Japan), according to the manufacturer's instructions.
Results
In vitro transcriptional targeting of AdRGD carrying Tyr or TERT promoter
By using melanoma cells, nonmelanoma tumor cells, and normal cells, we initially investigated whether AdRGD 
Antitumor efficacy of HSVtk/GCV system using different promoter-regulated AdRGDs
In order to compare the suppression of tumor growth between tumor-specific promoter-carrying AdRGD and universal promoter-carrying AdRGD in HSVtk/GCV therapy, we intratumorally injected AdRGD-Tyr/HSVtk, AdRGD-TERT/HSVtk, or AdRGD-CMV/HSVtk into established B16BL6 melanoma, and then administered GCV intraperitoneally into these mice for 10 days. Tumor volume change after AdRGD-injection and survival rate are summarized in Figure 4 . Intratumoral injection with any HSVtk-expressing AdRGD could inhibit B16BL6 tumor growth in a vector dosage-dependent manner, and similar antitumor efficacy was observed between the AdRGD-Tyr/HSVtk and AdRGD-TERT/HSVtk groups. In addition, 10 8 PFU of AdRGD-Tyr/HSVtk or AdRGD-TERT/HSVtk were needed to achieve comparable tumor regression and prolonged survival in mice to 10 7 PFU of AdRGD-CMV/HSVtk, that is, AdRGD-CMV/HSVtk was 10 times more effective.
Distribution of transgene expression in mice after intratumoral injection with different promoter-regulated AdRGDs
While intratumoral injection of AdRGD is an excellent method for attaining local elevation of transgene expression, prevention of AdRGD-leakage from the injected tumor into systemic circulation is very difficult. 18 Therefore, analysis of AdRGD biodistribution after the intratumoral injection is important for predicting and suppressing adverse effects of HSVtk/GCV treatment. We measured luciferase activity of B16BL6 tumors and six major organs (liver, spleen, kidney, heart, lung, and brain) in mice 2 days after intratumoral injection with AdRGD-CMV/Luc, AdRGD-Tyr/Luc, or AdRGD-TERT/Luc at 10 6 -10 9 PFU (Table 1) . Injection of any type of AdRGD increased luciferase activity in B16BL6 tumors in a vector dosage-dependent manner, and AdRGD-CMV/Luc-injected tumors exhibited 6-60 times higher luciferase activity than tumors injected with AdRGD-Tyr/Luc or AdRGD-TERT/Luc at the same PFU. This finding correlated closely with the difference in vector dosage between the three AdRGD-types, which was required for effective regression of B16BL6 tumor (Fig 4) , indicating that the expression efficiency of HSVtk gene in tumor tissue is a critical factor for effectiveness of HSVtk/GCV treatment. In mice injected with AdRGD-CMV/Luc, luciferase activity was detected not only in the tumor but also in other organs, and more than 95% of total activity was observed in the liver. On the other hand, luciferase activity was not detectable in other organs from mice injected with AdRGD-Tyr/Luc at 10 6 -10 9 PFU or AdRGD-TERT/Luc at 10 6 or 10 7 PFU. Although gene expression was observed in the liver from mice injected with AdRGD-TERT/Luc at more than 10 8 PFU, these luciferase activities were negligible and equivalent to activity in mice administered AdRGD-CMV/Luc at 10 6 PFU. Our data clearly revealed that AdRGD carrying Tyr or TERT promoter, which induced sufficient gene expression in melanoma tissue, could suppress transgene expression in other organs based on vector dissemination from injected tumor into systemic circulation.
AdRGD containing tumor-specific promoter reduces systemic toxicity of HSVtk/GCV system To examine potential adverse effects of systemic leakage of the AdRGD-expressing suicide gene, mice were intravenously injected with AdRGD-CMV/HSVtk, AdRGD-Tyr/HSVtk, or AdRGD-TERT/HSVtk at 10 8 or 10 9 PFU, followed by intraperitoneal injection of GCV. Severe reduction of body weight was observed in the mice administered AdRGD-CMV/HSVtk at 10 8 PFU, whereas intravenous injection with AdRGD-Tyr/HSVtk or AdRGD-TERT/HSVtk did not induce considerable body weight change even at 10 9 PFU (Fig 5) . When transgene expression levels were measured in six major organs from mice 2 days after intravenous injection with AdRGD-CMV/Luc at 10 7 -10 9 PFU, the liver showed a marked increase in luciferase activity depending on vector dosage, and more than 99% of total luciferase activity was detected in the liver (Table 2) . On the other hand, the liver from mice injected with AdRGD-Tyr/Luc or AdRGD-TERT/Luc at 10 9 PFU showed 1-4 log order lower luciferase activity than that from mice injected with Established B16BL6 tumors in C57BL/6 mice were injected with each AdRGD at the indicated PFU in 50-ml PBS. After 2 days, the tumor, liver, spleen, kidney, heart, lung, and brain were removed and homogenized, and then luciferase activity in the homogenates was measured. All data represent the mean7SE of 5-6 mice. The mean background value of luciferase activity in each organ has been subtracted from the data. ND: luciferase activity was not detectable. , or n; 10 9 PFU) in 100-ml PBS were intravenously administered into C57BL/6 mice. Mice were treated with intraperitoneal injection of GCV for 6 days, and body weight was monitored every day. Relative body weight was calculated according to the formula described in the Materials and methods section. Each point represents the mean7SE of six mice.
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AdRGD-CMV/Luc at 10 times less vector dosage (10 8 PFU) . These data strongly suggested that body weight reduction in response to HSVtk/GCV treatment was correlated with liver damage, which exhibited the highest levels of unfavorable transgene expression. Furthermore, blood was collected from mice that were treated with each HSVtk-expressing AdRGD and GCV, and then serum levels of GOT and GPT, enzymatic biomarkers of hepatotoxicity, were measured. As shown in Table 3 , serum levels of GOT and GPT drastically increased in mice injected with AdRGD-CMV/HSVtk at 10 8 PFU. Although the histological examination of the liver did not show remarkable pathological change, the gallbladder of these mice was remarkably hypertrophied, and the serum showed a state of bilirubinemia (data not shown). In contrast, mice injected with AdRGD-Tyr/ HSVtk or AdRGD-TERT/HSVtk at 10 8 or 10 9 PFU exhibited low GOT and GPT levels, less than one-tenth of those in mice administered AdRGD-CMV/HSVtk at 10 8 PFU. Therefore, AdRGD-Tyr/HSVtk and AdRGD-TERT/HSVtk could reduce systemic adverse effects, mainly hepatotoxicity, of the HSVtk/GCV system by transcriptional targeting of the HSVtk gene to melanoma tissue.
Discussion
Suicide gene therapy using the HSVtk/GCV system is a potential cancer treatment in which therapeutic efficacy relies on the transduction efficiency of HSVtk gene into tumor. Among the currently available vector systems, Ad is frequently used in research and development of gene therapy due to highly efficient transduction in a wide variety of cell types and tissues regardless of the mitotic status of the cell. However, the efficiency of gene transfer using conventional Ad, which is derived from human adenovirus serotype 2 or 5, varies widely depending on the tissue origin of target cells. In particular, melanoma, which is an important target for gene therapy, requires high Ad dosage for sufficient gene expression because of the low expression or deficiency of the primary Adreceptor, that is, the coxsackie-adenovirus receptor, on the cell surface. 14, 36 In this regard, we previously demonstrated that AdRGD, which possesses av-integrin tropism, was a potent vector system for gene transduction in melanoma, and that the intratumoral injection of AdRGD-expressing cytokine or HSVtk gene could more effectively induce tumor regression in established murine B16BL6 melanoma model than conventional Ad. [14] [15] [16] [17] Although these results suggested that AdRGD could contribute to the establishment of efficacious suicide gene therapy for melanoma, gene expression had to be localized in tumor tissue when AdRGD encoding HSVtk gene was intratumorally injected in order to assure the safety of the HSVtk/GCV system. In fact, we found that about 1% of AdRGD that was carefully injected into B16BL6 tumor leaked from tumors into systemic circulation, although AdRGD could reduce systemic vector dissemination by its superior gene transduction to melanoma as compared with conventional Ad. 18 In the present study, we attempted to construct a specialized AdRGD and optimized its applicability to the HSVtk/ GCV treatment for melanoma by using Tyr (melanomaspecific) or TERT (tumor-specific) promoter. C57BL/6 mice were intravenously injected with each AdRGD at the indicated PFU in 100-ml PBS. After 2 days, the liver, spleen, kidney, heart, lung, and brain were removed and homogenized, and then luciferase activity in the homogenates was measured. All data represent the mean7SE of six mice. The mean background value of luciferase activity in each organ has been subtracted from the data. ND: luciferase activity was not detectable. All data represent the mean7SD of six mice.
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